On ketamine.

Ketamine is having a strange cultural moment. It is simultaneously the subject of serious clinical interest — the TGA approved esketamine nasal spray (Spravato) for treatment-resistant depression in 2021, and ketamine-assisted therapy clinics are operating in Australia — and a recreational drug present in urban social scenes, festival culture, and some professional social networks with a profile that has evolved significantly over the past decade.

Consumer-facing information has not kept up with either development. The clinical literature is technical and inaccessible. The recreational harm reduction information oscillates between alarm and dismissal. The person who uses ketamine occasionally at parties and wants an honest, calibrated account of what the evidence says is not well served.

This is an attempt to be that account.

What ketamine is and does

Ketamine is a dissociative anaesthetic — it was developed and is still used clinically as an anaesthetic agent, and its effects reflect this. At anaesthetic doses, it produces unconsciousness and analgesia. At sub-anaesthetic doses — the recreational range — it produces a spectrum of effects:

At low doses: mild perceptual distortion, dissociation from the body, altered sense of time, relaxation, and reduced inhibition. In social contexts, it produces a specific quality of intoxication that many users find distinct from alcohol and stimulants.

At higher doses: more profound dissociation, ego dissolution, the "k-hole" — an immersive, often described as visually and experientially intense, state of dissociation that some users actively seek and others find overwhelming. At this level, motor coordination is significantly impaired and the user is effectively immobile.

The mechanism is NMDA receptor antagonism — blocking glutamate's primary receptor. This is the same mechanism underlying ketamine's antidepressant effect, which is why the clinical and recreational pharmacology are related but not identical in their implications.

The therapeutic use context

Ketamine's antidepressant properties were documented serendipitously in the late 1990s and have since been the subject of substantial clinical research. Intravenous ketamine infusion and intranasal esketamine have demonstrated rapid antidepressant effects — often within hours rather than the weeks required by conventional antidepressants — in people with treatment-resistant depression.

This therapeutic evidence is real and significant. It does not, however, translate to a conclusion that recreational ketamine use is therapeutically beneficial or that self-medication with recreational ketamine is a sound approach to depression. The clinical use involves controlled dosing, medical supervision, and integration support — a very different context from recreational use.

Some people who use ketamine recreationally do so partly for mood management — to access a dissociative state during periods of low mood or stress. The evidence does not support this as a reliable or safe strategy, and the relationship between recreational ketamine use and the development or maintenance of depression is complex.

The specific risks: bladder

The most distinctive and serious health consequence of regular ketamine use is ketamine-induced uropathy — damage to the urinary tract, specifically the bladder, that produces chronic pain, severely reduced bladder capacity, and in serious cases requires surgical intervention up to and including cystectomy.

Ketamine cystitis was first described in the clinical literature in 2007 and has been documented with increasing frequency in recreational ketamine users. The mechanism is not fully established; ketamine and its metabolites appear to be directly toxic to bladder tissue with chronic exposure. Symptoms include urinary frequency, urgency, pain on urination, and haematuria.

The critical clinical feature is that ketamine uropathy is progressive with continued use and can be substantially reversed by early cessation, but becomes increasingly irreversible with prolonged heavy use. This is information that anyone using ketamine regularly should have. It is the risk that distinguishes ketamine's harm profile from most other recreational drugs at comparable use frequency.

Risk factors for uropathy appear to include frequency of use (daily or near-daily use has the highest risk), dose, duration of individual sessions, and possibly individual susceptibility. Occasional low-dose recreational use is substantially lower risk than regular heavy use, but the dose-response relationship is not clearly established at the population level.

Mental health effects and dependence

The evidence on ketamine and mental health at recreational use levels is less developed than for stimulants or alcohol, partly because the phenomenon is relatively recent and the recreational user population is difficult to study.

Animal studies and human case reports suggest that heavy ketamine use is associated with cognitive impairment — particularly in memory and executive function — that may persist beyond the acute intoxication period. The reversibility of these effects with prolonged abstinence is uncertain.

Psychological dependence on ketamine — craving, increased use over time, difficulty cutting back — is well documented, though physical withdrawal (in the sense of physiological dependence with a discrete withdrawal syndrome) is not a prominent feature. The dependence tends to be psychological and often has a specific character: the use of the dissociative state as an avoidance strategy for emotional pain that, over time, has replaced rather than supplemented other coping resources.

Frequent use is associated with worsening depressive symptoms in non-clinical populations — the opposite of its acute antidepressant effect. This may reflect tolerance to the antidepressant mechanism, the consequences of associated poor sleep and lifestyle, or the use of ketamine as an avoidance strategy for emotional processing that, not being processed, compounds.

What accurate information looks like

The "is this fine?" question for occasional ketamine use at parties is genuinely different from the same question for someone using ketamine several times a week. The risk profile is dose and frequency dependent in important ways.

What the evidence supports:

• The bladder risk is real, progressive, and partially reversible — it is the most important specific risk for regular users to understand
• Cognitive and psychological effects appear at heavy/frequent use that are less concerning at genuinely occasional use
• The therapeutic framing in the news does not translate to recreational self-medication being safe or effective
• Frequency tracking — knowing how often you're actually using — is more useful than impression, which tends to systematically underestimate

---

ayodee tracks substance use and mood without clinical framing, labels, or identity attached. Anonymous, no email required. ayodee.app.